Chelsea Therapeutics, Inc. Initiates Northera Study 306 in Neurogenic Orthostatic Hypotension Associated With Parkinson’s Disease and Provides Update on Status of Phase II Study of CH-4051 in Rheumatoid Arthritis

CHARLOTTE, N.C., June 29, 2010 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced the initiation of Study 306, a pivotal Phase III trial evaluating the efficacy of NORTHERA™, an oral synthetic precursor of norepinephrine, for the treatment of symptomatic neurogenic orthostatic hypotension (NOH) associated with Parkinson's disease.